B-lymphocyte stimulator and a proliferation-inducing ligand serum levels in IgA-deficient patients with and without celiac disease

Annals of the New York Academy of Sciences

Volumn 1173, Issue , 2009, Pages 268-273

  Fabris, Martina ^b   De Vita, Salvatore ^a   Visentini, Daniela ^a   Fabro, Cinzia ^a   Picierno, Alessia ^b   Lerussi, Alice ^a   Villalta, Danilo ^c   Alessio, Maria Grazia ^d   Tampoia, Marilina ^e   Tonutti, Elio ^b  

^a Clinic of Rheumatology   (Italy)

^b UNIVERSITY HOSPITAL OF UDINE   (Italy)

^c General Hospital of Pordenone   (Italy)

^d OSPEDALI RIUNITI   (Italy)

^e POLICLINICO   (Italy)

Author keywords

APRIL; Autoimmunity; BLyS; Celiac disease; IgA deficiency

Indexed keywords

APRIL PROTEIN; B CELL ACTIVATING FACTOR; IMMUNOGLOBULIN A;

ADOLESCENT; ADULT; AGED; AUTOIMMUNE DISEASE; B LYMPHOCYTE ACTIVATION; CELIAC DISEASE; CHILD; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE OVEREXPRESSION; GENETIC RISK; HETEROZYGOSITY; HUMAN; IMMUNOGLOBULIN A DEFICIENCY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN PRODUCTION; IMMUNOSTIMULATION; MALE; PRESCHOOL CHILD; PROTEIN BLOOD LEVEL; SCHOOL CHILD; UPREGULATION;

EID: 70049108148     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.04628.x     Document Type: Conference Paper

References (24)

1. Cunningham-Rundles, C. 2001. Physiology of IgA and IgA deficiency. J. Clin. Immunol. 21: 303-309.
2. Liblau, R.S. & J.F. Bach. 1992. Selective IgA deficiency and autoimmunity. Int. Arch. Allergy Immunol. 99: 16-27.
3. McGowan, K.E. et al. 2008. Celiac disease and IgA deficiency: complications of serological testing approaches encountered in the clinic. Clin. Chem. 54: 1203-1209.
4. Schaffer, F.M. 2008. Clinical assessment and management of abnormal IgA levels. Ann. Allergy Asthma Immunol. 100: 280-282.
5. Aghamohammadi, A. et al. 2008. Progression of selective IgA deficiency to common variable immunodeficiency. Int. Arch. Allergy Immunol. 147: 87-92.
6. Schaffer, A.A. et al. 2007. Deconstructing common variable immunodeficiency by genetic analysis. Curr. Opin. Genet. Develop. 17: 201-121.
7. Salzer, U. et al. 2008. Relevance of biallelic versus monoallelic TNFRSF13B mutations in distinguishing disease-causing from risk-increasing TN-FRSF13B variants in antibody deficiency syndromes. Blood; Nov 3, online published.
8. von Bulow, G.U. et al. 2001. Regulation of the T-independent humoral response by TACI. Immunity 14: 573-582.
9. Schneider, P. 2005. The role of April and BAFF in lymphocyte activation. Curr. Opin. Immunol. 17: 282-289.
10. Mackay, F. et al. 2005. The BAFF/April system: an important player in systemic rheumatic diseases. Curr. Dir. Autoimmun. 8: 243-265.
11. Castigli, E. et al. 2004. Impaired IgA class switching in April-deficient mice. Proc. Natl. Acad. Sci USA 101: 3903-3908.
12. Castigli, E. & R.S. Geha. 2007. TACI, isotype switching, CVID and IgAD. Immunol. Res. 38: 102-111.
13. Fabris, M. et al. 2007. Elevated B cell-activating factor of the TNF family in celiac disease. Scan. J. Gastroen-therol. 42: 1434-1439.
14. Knight, A.K. et al. 2007. High serum levels of BAFF, April, and TACI in common variable immunodeficiency. Clin. Immunol. 124: 182-189.
15. Jin, R. et al. 2008. Age-related changes in BAFF and APRIL profiles and upregulation of BAFF and APRIL expression in patients with primary antibody deficiency. Int. J. Mol. Med. 21: 233-238.
16. Cerutti, A. 2008. The regulation of IgA class switching. Nat. Rev. Immunol. 8: 421-434.
17. Husain, Z. et al. 2006. Increased apoptosis of CD20+ IgA+ B cells is the basis for IgA deficiency: the molecular mechanism for correction in vitro by IL-10 and CD40L. J. Clin. Immunol. 26: 113-125.
18. Lavie, F. et al. 2007. Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production. Ann. Rheum. Dis. 66: 700-703.
19. Salavoura, K. et al. 2008. Development of cancer in patients with primary immunodeficiencies. Anticancer Res. 28: 1263-1269.
20. Fabris M. et al. 2007. B-Lymphocyte Stimulator (BLyS) upregulation in mixed cryoglobulinemia syndrome and hepatitis C virus infection. Rheumatology 46: 37-43.
21. Quartuccio, L., V. De Re, M. Fabris, et al. 2006. Atypical lymphoproliferation progressing into B-cell lymphoma in rheumatoid arthritis treated with different biological agents: clinical course and molecular characterization. Haematologica 91: 691-694.
22. Pan-Hammarström, Q. et al. 2007. Reexamining the role of TACI coding variants in common variable immunodeficiency and selective IgA deficiency. Nat. Genet. 39: 429-430.
23. Treml, J.F. et al. 2009. The BLyS family: toward a molecular understanding of B cell homeostasis. Cell Biochem. Biophys. 53: 1-16.
24. De Vita, S., L. Quartuccio & M. Fabris. 2008. Hepatitis C virus infection, mixed crioglobulinemia cryo-globulinemia and BLyS upregulation: Targeting the infectious trigger, the autoimmune response, or both? Autoimmun. Rev. 8: 95-99.